2vin: Difference between revisions
New page: left|200px<br /><applet load="2vin" size="350" color="white" frame="true" align="right" spinBox="true" caption="2vin, resolution 1.9Å" /> '''FRAGMENT-BASED DISCOV... |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Fragment-based lead discovery has been applied to urokinase-type | Fragment-based lead discovery has been applied to urokinase-type plasminogen activator (uPA). The (R)-enantiomer of the orally active drug mexiletine 5 (a fragment hit from X-ray crystallographic screening) was the chemical starting point. Structure-aided design led to elaborated inhibitors that retained the key interactions of (R)-5 while gaining extra potency by simultaneously occupying neighboring regions of the active site. Subsequent optimization led to 15, a potent, selective, and orally bioavailable inhibitor of uPA. | ||
==About this Structure== | ==About this Structure== | ||
2VIN is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=ACT:'>ACT</scene>, <scene name='pdbligand=SO4:'>SO4</scene> and <scene name='pdbligand=505:'>505</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/U-plasminogen_activator U-plasminogen activator], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.73 3.4.21.73] Known structural/functional Sites: <scene name='pdbsite=AC1:Act Binding Site For Chain A'>AC1</scene>, <scene name='pdbsite=AC2:So4 Binding Site For Chain A'>AC2</scene> and <scene name='pdbsite=AC3:505 Binding Site For Chain A'>AC3</scene>. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2VIN OCA]. | 2VIN is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=ACT:'>ACT</scene>, <scene name='pdbligand=SO4:'>SO4</scene> and <scene name='pdbligand=505:'>505</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/U-plasminogen_activator U-plasminogen activator], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.73 3.4.21.73] Known structural/functional Sites: <scene name='pdbsite=AC1:Act+Binding+Site+For+Chain+A'>AC1</scene>, <scene name='pdbsite=AC2:So4+Binding+Site+For+Chain+A'>AC2</scene> and <scene name='pdbsite=AC3:505+Binding+Site+For+Chain+A'>AC3</scene>. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2VIN OCA]. | ||
==Reference== | ==Reference== | ||
| Line 17: | Line 17: | ||
[[Category: Chessari, G.]] | [[Category: Chessari, G.]] | ||
[[Category: Congreve, M.]] | [[Category: Congreve, M.]] | ||
[[Category: Cowan, S | [[Category: Cowan, S R.]] | ||
[[Category: Frederickson, M.]] | [[Category: Frederickson, M.]] | ||
[[Category: Matthews, J | [[Category: Matthews, J E.]] | ||
[[Category: Mcmenamin, R.]] | [[Category: Mcmenamin, R.]] | ||
[[Category: Smith, D.]] | [[Category: Smith, D.]] | ||
[[Category: Vinkovic, M.]] | [[Category: Vinkovic, M.]] | ||
[[Category: Wallis, N | [[Category: Wallis, N G.]] | ||
[[Category: 505]] | [[Category: 505]] | ||
[[Category: ACT]] | [[Category: ACT]] | ||
| Line 44: | Line 44: | ||
[[Category: zymogen]] | [[Category: zymogen]] | ||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 18:56:19 2008'' | ||
Revision as of 16:56, 21 February 2008
|
FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR
Overview
Fragment-based lead discovery has been applied to urokinase-type plasminogen activator (uPA). The (R)-enantiomer of the orally active drug mexiletine 5 (a fragment hit from X-ray crystallographic screening) was the chemical starting point. Structure-aided design led to elaborated inhibitors that retained the key interactions of (R)-5 while gaining extra potency by simultaneously occupying neighboring regions of the active site. Subsequent optimization led to 15, a potent, selective, and orally bioavailable inhibitor of uPA.
About this Structure
2VIN is a Single protein structure of sequence from Homo sapiens with ACT, SO4 and 505 as ligands. Active as U-plasminogen activator, with EC number 3.4.21.73 Known structural/functional Sites: AC1, AC2 and AC3. Full crystallographic information is available from OCA.
Reference
Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator., Frederickson M, Callaghan O, Chessari G, Congreve M, Cowan SR, Matthews JE, McMenamin R, Smith DM, Vinkovic M, Wallis NG, J Med Chem. 2008 Jan 24;51(2):183-6. Epub 2007 Dec 29. PMID:18163548
Page seeded by OCA on Thu Feb 21 18:56:19 2008
Proteopedia Page Contributors and Editors (what is this?)
- Pages with broken file links
- Homo sapiens
- Single protein
- U-plasminogen activator
- Callaghan, O.
- Chessari, G.
- Congreve, M.
- Cowan, S R.
- Frederickson, M.
- Matthews, J E.
- Mcmenamin, R.
- Smith, D.
- Vinkovic, M.
- Wallis, N G.
- 505
- ACT
- SO4
- Blood coagulation
- Egf-like domain
- Fibrinolysis
- Glycoprotein
- Hydrolase
- Inhibitor
- Kringle
- Pharmaceutical
- Phosphorylation
- Plasminogen activation
- Polymorphism
- Protease
- Secreted
- Serine protease
- Urokinase-type plasminogen activator
- Zymogen
